Epilepsy is a debilitating neurological condition characterized by recurrent seizures that imparts a social and economic burden on patients and their caregivers. The goal of therapy is to prevent…
Ushering in a New Era of Cancer Immunotherapies in NSCLC, Malignant Melanoma, Renal Cell Carcinoma, and SCCHN The field of cancer immunotherapy has witnessed considerable advances over the past few…
Five premium-priced therapies – Xtandi (Medivation/Astellas Pharma), Provenge (Dendreon), and Xofigo (Algeta/Bayer HealthCare), Zytiga (Janssen), and Jevtana (Sanofi) – are approved in Europe…
The malignant melanoma treatment landscape is dynamic and continues to undergo significant changes. Since 2011, three immune checkpoint inhibitors and four BRAF- or MEK-targeted agents have gained…
Last Updated 15 September 2015 Ulcerative colitis (UC) affects approximately 1.25 million people across the major markets. Aminosalicylates and corticosteroids are routinely prescribed for mild…
Medical devices companies are constantly searching for growth opportunities. The largest opportunities lie within untapped emerging markets and the development of innovative technology. Analyzing…
Type 2 diabetes (T2D) is a chronic, progressive metabolic disease in which the body becomes resistant to insulin, most often as a result of obesity and sedentary lifestyle. The primary goal of…
In 2014, total sales for neuropathic pain (NP) in the seven major pharmaceutical markets under study (United States, France, Germany, Italy, Spain, United Kingdom, and Japan) were estimated to be…
Patients surgically treated for orthopedic indications have a unique set of characteristics when compared with other surgical patients; critically, surgical treatment for these patients is often…
Improving survival among those with advanced cancer along with a high rate of cancer-related pain in this patient population will lead to steady growth in the prevalence of cancer pain in the seven…
Improving survival among those with advanced cancer along with a high rate of cancer-related pain in this patient population will lead to steady growth in the prevalence of cancer pain in the seven…
For the estimated 2 million diagnosed patients in the United States who suffer from rheumatoid arthritis (RA), there are multiple prescription therapies that are available for treating the…
Outpatient parenteral antimicrobial therapy (OPAT) is a convenient mechanism for treating patients with infections that require intravenous (IV) antibiotic drugs but are clinically stable and do…
Improving survival among those with advanced cancer along with a high rate of cancer-related pain in this patient population will lead to steady growth in the prevalence of cancer pain in the…
With a series of recent advancements in pharmaceutical market access, Japan is transforming into a market where companies with innovative products can benefit from more opportunities. In addition,…
